- Novel Coronavirus
-
Drug Discovery Services
- Antiviral Drug Discovery
- Complement Therapy
- SARS-CoV-2 Aptamers
- Antisense Oligonucleotides
- Protease Inhibitors
- Inhibitor of Host Cell Protease
- Abelson Kinase Inhibitors
- RNA Synthesis Inhibitors
- Nucleoside Analogue
- Neuraminidase Inhibitors
- Neutralizing Antibody
- Antiviral Peptide
- Broad-spectrum Antiviral Drug
- Anti-Inflammatory Drugs
- High-Throughput Screening
- Vaccine Discovery
- Evaluation Platforms for SARS-CoV-2 Drugs
- Antiviral Drug Discovery
- IVD Immunoassays
- Products
- Resources
- About Us
ACE2-TMPRSS2 co-enhanced RT4 Cell Line (CAT#: VCeL-Wyb051)
- Product Overview
- ACE2-TMPRSS2 co-enhanced human bladder carcinoma cell
- Quantity
- 3-5×106 cells/ml
- Target
- SARS-CoV-2
- Applications
- Effective tools for studying COVID-19 drugs and vaccines.
- Cell Type
- ACE2 and TMPRSS2 Co-Enhanced Cell Line
- Organism
- RT4 cells
- Growth Properties
- Adherent
- Fluid Renewal
- 2 to 3 times / week
- Form
- Frozen Cryovial
- Biosafety Level
- 1
- Alternative Names
- ACE2-TMPRSS2 co-enhanced RT4 Cell Line
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.
For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.